Sight Sciences Launches OMNI Ultra Surgical System for Glaucoma Treatment
Event summary
- Sight Sciences debuts the OMNI Ultra Surgical System at the 2026 AAO Annual Meeting in New Orleans.
- OMNI Ultra is the latest advancement in the company's ab interno canaloplasty platform, offering enhanced versatility and procedural control.
- The system is designed to reduce intraocular pressure by addressing all three known areas of resistance in the conventional aqueous outflow pathway.
- OMNI Ultra can be used as a standalone procedure or in combination with cataract surgery in adult patients with primary open-angle glaucoma.
The big picture
Sight Sciences continues to innovate in the interventional glaucoma space, reinforcing its position as a pioneer in ab interno canaloplasty. The launch of OMNI Ultra underscores the company's commitment to addressing the root causes of glaucoma through procedural intervention. This strategic move aligns with broader industry trends towards minimally invasive and implant-free solutions for eye care.
What we're watching
- Market Adoption
- How quickly OMNI Ultra will be adopted by surgeons and integrated into clinical practice.
- Competitive Positioning
- Whether Sight Sciences can maintain its leadership in the implant-free, minimally invasive glaucoma surgery category.
- Regulatory Compliance
- The pace at which the company can secure additional regulatory clearances for OMNI Ultra in other markets.
Related topics